In addition, the present study’s longitudinal data showed for the first time that serum CHIT1 activity and YKL-40 concentration are stable in IPF patients treated with antifibrotics and may have the potential as candidate prognostic biomarkers in IPF clinical practice. This evidence concerns the gene CHI3L1 and idiopathic pulmonary fibrosis.